Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress

Kidney International

Volumn 65, Issue 1, 2004, Pages 238-244

  Wuerzner, Grégoire ^a   Chicléro, Arnaud ^a   Maillard, Marc ^a   Nussberger, Jürg ^a   Brunner, Hans R ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

AT1 receptor blocker; Candesartan; Lower body negative pressure; Renin angiotensin aldosterone system; Sodium; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; NEUROHORMONE; SODIUM; WATER;

ADULT; ARTICLE; BLOOD VOLUME; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURESIS; DOSE RESPONSE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY TUBULE FUNCTION; LOWER BODY NEGATIVE PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NORMAL HUMAN; ORTHOSTATIC STRESS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SODIUM BALANCE; SODIUM EXCRETION; SODIUM RETENTION; STANDING; STRESS; URINARY EXCRETION;

EID: 0347362494     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00376.x     Document Type: Article

References (34)

1. SCHRIER RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 319:1127-1134, 1988
2. DIBONA GF, KOPP UC: Neural control of renal function. Physiol Rev 77:75-197, 1997
3. SCHRIER RW, ABRAHAM WT: Hormones and hemodynamics in heart failure. N Engl J Med 34:577-585, 1999
4. BENEDICT CR, FRANCIS GS, SHELTON B, et al: Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol 75:1151-1157, 1995
5. MCKELVIE RS, YUSUF S, PERICAK D, et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100:1056-1064, 1999
6. PITT B, POOLE-WILSON PA, SEGAL R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587, 2000
7. COHN JN, VALSARTAN HEART FAILURE TRIAL INVESTIGATORS, TOONONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001
8. MAGRI P, RAO MA, CANGIANIELLO S, et al: Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 98:2849-2854, 1998
9. STAAHLTOFT D, NIELSEN S, JANJUA NR, et al: Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. Am J Physiol 282:F307-F315, 2002
10. DIBONA GF, JONES SY, SAWIN LL: Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure. Am J Physiol 274(2 Pt 2):H636-H641, 1998
11. WÜRZNER G, CHIOLERO A, MAILLARD M, et al: Renal and neurohormonal responses to increasing levels of lower body negative pressure in men. Kidney Int 60:1469-1476, 2001
12. STEINHAUSLIN F, BURNIER M, MAGNIN JL, et al: Fractional excretion of trace lithium and uric acid in acute renal failure. J Am Soc Nephrol 4:1429-1437, 1994
13. BURNIER M, RUTSCHMANN B, NUSSBERGER J, et al: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339-347, 1993
14. MAGNIN JL, DECOSTERD LA, CENTENO C, et al: Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: Variability of urine matrices circumvented by cation exchange solid phase extraction. Pharm Acta Helv 71:237-246, 1996
15. THOMSEN K, SHIRLEY DG: The validity of lithium clearance as an index of sodium and water delivery from the proximal tubules. Nephron 77:125-138, 1997
16. NUSSBERGER J, FASANELLA D'AMORE T, PORCHET M, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 9:39-44, 1987
17. NUSSBERGER J, WAEBER B, BRUNNER HR, et al: Highly sensitive microassay for aldosterone in unextracted plasma: Comparison with two other methods. J Lab Clin Med 104:789-796, 1984
18. NUSSBERGER J, MOOSER V, MARIDOR G, et al. Caffeine-induced diuresis and atrial natriuretic peptides. J Cardiovasc Pharmacol 15:685-691, 1990
19. TIDGREN B, HJEMDAHL P, THEODORSSON E, NUSSBERGER J: Renal neurohormonal and vascular responses to dynamic exercise in humans. J Appl Physiol 70:2279-2286, 1991
20. GILBERT CA, BRICKER LA, SPRINGFIELD WT, JR, et al. Sodium and water excretion and renal hemodynamics during lower body negative pressure. J Appl Physiol 21:1699-1704, 1966
21. HIRSCH AT, LEVENSON DJ, CUTLER SS, et al: Regional vascular responses to prolonged lower body negative pressure in normal subjects. Am J Physiol 257:H219-H225, 1989
22. FRANK H, SCHOBEL HP, VITKOWSKY J, et al. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int 63:617-623, 2003
23. WONG PC, HART SD, TIMMERMANS PB: Effect of angiotensin II antagonism on canine renal sympathetic nerve function. Hypertension 17(6 Pt 2):1127-1134, 1991
24. BURNIER M, BIOLLAZ J, BRUNNER DB, BRUNNER HR: Alpha-and beta-adrenoceptor blockade in normotensive and DOC-hypertensive rats: Plasma vasopressin and vasopressin pressor effect. J Pharmacol Exp Ther 224:222-227, 1983
25. OHLSTEIN EH, BROOKS DP, FEUERSTEIN GZ: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not losartan, valsartan, or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 55:244-251, 1997
26. CERVENKA L, WANG CT, NAVAR LG: Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol 274(5 Pt 2):F940-F945, 1998
27. CERVENKA L, NAVAR LG: Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan. J Am Soc Nephrol 10 (Suppl 11): S197-S201, 1999
28. NAVAR LG, HARRISON-BERNARD LM, IMIG JD, et al. Renal responses to AT1 receptor blockade. Am J Hypertens 13(1 Pt 2): p. 45S-54S, 2000
29. BUTER H, NAVIS GY, WOITTIEZ AJ, et al. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 54:953-958, 1999
30. FRIDMAN K, ANDERSSON OK, WYSOCKI M, FRIBERG P: Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 11 (Suppl 2): S43-S44, 1997
31. HOLLENBERG NK, PRICE DA, FISHER ND, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 63:172-178, 2003
32. FRIDMAN K, WYSOCKI M, FRIBERG P, ANDERSSON OK: Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hypertens 13:1045-1048, 2000
33. KAWABATA M, TAKABATAKE T, OHTA H, et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Pressure (Suppl) 3:117-121, 1994
34. KOPP UC, CICHA MZ, SMITH LA: Impaired responsiveness of renal mechanosensory nerves in heart failure: Role of endogenous angiotensin. Am J Physiol 284:R116-R124, 2003